Home / Corporate news / Analys Peptonic: Nya pengar för tillväxt

Analys Peptonic: Nya pengar för tillväxt

- June 10, 2019

Basscenariot visar på en riktkurs om 1,40 kr, vilket är avsevärt högre än teckningskursen på 0,83 kr i den pågående företrädesemissionen.

Läs hela artikeln på aktiespararna.se »
Ladda ner analysen (PDF) »

About us

PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.

Analys Peptonic: Nya pengar för tillväxt

All press releases on Spotlightstockmarket.com

Contact us

About us

Contact us

Dataskyddspolicy

Navigation